The same tired old cooks in the Infectious Diseases kitchen are once again attempting to force-feed a bitter confection to an unreceptive and fortunately already Lyme-educated audience. And having failed to convince thousands of American patients and their doctors that their illness is not “all in their heads”, the “spew crew” are trying their luck on the UK media circuit. Here is the article in question:
In a recent article by the BBC News (Washington), Jane O’Brien tells readers that “PTLDS” or post-treatment Lyme disease syndrome is supposed to be “controversial” because “nobody” knows what causes it. Now I don’t really fault the reporter, except that the article is hardly objective, or even accurate in its factoids. If you are going to report something on international news, you can at least get the facts straight.
For one, the article assumes that there actually is such an entity as “PTLDS.” (I have to admit that I had to look up its meaning because I began to say “post-traumatic Lyme disease syndrome.” When you think about it, when and if patients are ever healed completely, they will be suffering from some sort of post-traumatic stress disorder from the incredible denial that surrounds this insidious illness.)
For clarification’s (and the reporter’s) sake, I am here to state that there really is no such thing as PTLDS. The whole “post-treatment” Lyme disease “syndrome” was an idea that appears to have been invented by Connecticut Rheumatologist Dr. Allen C. Steere. Indeed the illustrious doctor seems to have felt somewhat ambiguous or inconclusive about his own research findings, and merely postulated at one time that there may be some sort of an “autoimmune” disorder following a Lyme infection in patients who received basic antibiotic treatment.
Over time however, this so-called “possible” autoimmune disorder was changed to an actual syndrome with the moniker of PTLDS. This non-existent syndrome speculation was quickly adopted by the likes of those such as Dr. Baker, as a means of giving “chronic” illness the boot. Imagine the pharmaceutical patents that could be invented to “treat” the symptoms of an indeterminate syndrome…symptoms which are so lengthy that I will not add them here, lest they overwhelm this blog entry.
It appears clear that even Dr. Steere was unsure of a thing called “PTLDS.” He only speculated that it was possible.
To clarify the so-called “post-Lyme syndrome” that certain Lyme denialists continue to spoon-feed the media as if scientific fact; I take readers back to the first place this supposed syndrome ever appeared in a published source…at least as far as I have seen it (and I have read a lot of scientific papers, patents, etc. over the years).
One problem I often see is that some things in the scientific realm which should best remain inside the heads of those designing new devices, have a way of being recorded within the patent invention text, even if the thoughts are little more than wispy, fleeting postulations. If intentionally added, then in the absence of a stronger conclusion, such comments may be recorded if only in an attempt to corner the market for intellectual property purposes.
There the innocent speculation might sit stoic, yet relatively harmless until stumbled upon by an eager exploiter where it is reanimated like an unruly, adopted child. Then in a game of “telephone” gone wrong, the idea is repeated and twisted often enough that over time it becomes morphology identical to the spirochetes of Lyme disease. The idea and intent of its humble origins is quickly forgotten as the phrase takes on a new life as the centerpiece of a medico-political agenda in a good old boy’s club of infectious disease researchers — some of whom do not even treat patients, and whom write guidelines and publish anti-chronic Lyme agendas, presumably to protect profit interests of major corporations and pharmaceutical companies.
Never mind the imaginary “syndrome” has never been supported by any scientific evidence whatsoever that there is a.) any “autoimmune” disorder; or b.) that all patients suffering from this supposed syndrome do not have Borrelia burgdorferi (Bb) or Lyme spirochetes inside their bodies. Since the bugs are hard to culture because they hide out in places sequestered by the immune system, only the most sensitive and specialized laboratory tests are able to culture them. But we can talk to Dr. Alan Barbour about how difficult these spirochetes are to culture, he has some experience modifying culture mediums to isolate these spirochetes.
In this day of “evidence-based” medicine, the invention of a diagnosis for an unexplained illness is becoming more commonplace, and it is a convenient boon for pharmaceutical companies and vaccine patent holders alike — including some of the Baker’s Dozen infectious disease doctors about whom I write about in some of my books.
Therein lay the clues to the “real” Lyme disease “syndrome,” however the majority of the public and the well-meaning reporters have not been exposed to the truth found in the pages of these well-well researched tomes. The evidence however is overwhelmingly real, and when taken from some of the parties responsible for denying chronic Lyme, that this disease is chronic, debilitating; that patients have persisting infections even after antibiotic treatment; and that this information is well-known among scientific experts, including those whom patent all things borrelia-related, and whom often publicly claim the “PTLDS” defense so that a slow-played epidemic, which according to some bakers, is not really an epidemic. So “no worries…but stay out of the woods, away from lakes, and check your own living room as these tiny terrorists climb up your socks unannounced.
Are we ready for a pinch of the salty truth?
Check this out. From a Yale University diagnostic test patent (#5,618,533) we find that truth and baking doesn’t belong in the Lyme kitchen. Remember first and foremost that patent inventions are truthful sworn statements which must be so in order to gain intellectual property rights.
This particular Yale patent was invented by scientists Richard Flavell, Erol Fikrig, and Robert Berland. It was filed in December 1993, just ten months before the CDC-sponsored Dearborn conference that would standardize Lyme disease surveillance criteria, as well as diagnostic tests for Lyme disease. (The conference did not result in the recommended use of this particularly useful diagnostic test, which is interesting.) The patent discusses the various stages of Lyme disease, including an advanced stage of severe disability that is the result of persistence of the Bb organism. From the patent we read:
“Stage three, or late infection, is defined as persistent infection, and can be severely disabling. Chronic arthritis, and syndromes of the central and peripheral nervous system appear during this stage, as a result of the ongoing infection and perhaps a resulting auto-immune disease…”
Ah, “perhaps” is the operative word. “Perhaps” is unsupported by scientific logic or by evidence-based facts. The patent continues:
“Early in human infection, antibodies are generated primarily against the 41-kDa flagellar protein. In later stages, antibodies to the outer surface proteins OspA and OspB, among others, appear…Further, the sera from patients with neurologic manifestations of Lyme disease have IgM antibodies that bind human axons; binding is weak or absent in patients without neurologic disease….
These statements support that infected patients do not make adequate antibodies during early infection; particularly in patients whom do not have neurologic symptoms. The patent continues:
“Treatment of early disease is usually effective, however the cardiac, arthritis and nervous system disorders associated with the later stages often do not respond to therapy [A.C. Steere, “Lyme Disease,” N. Engl. J. Med., 321, pp. 586-96 (1989)].”
The expert quoted within the patent is Connecticut Rheumatologist Dr. Allen C. Steere, who was also a key attendee at the Dearborn conference; and a major “kingpin” if you will, of most of the Lyme disease precedent-setting activities over the past four decades.
In another paper co-authored by Lyme notables and Steere colleagues Gary P. Wormser, Erol Fikrig, Robert Schoen, and Ira Schwartz; the persistence of the Bb spirochete is discussed, particularly for its ability to persist in different organs and in the joints due to two spirochetal genes, identified as “BmpA” and “BmpB.” According to the paper:
“It is likely that the diverse metabolic or immune microenvironments within mammalian tissues may influence the ability of the B. burgdorferi to persist in different organs…certain sites may afford survival advantages because of protection from host responses, binding ligands, or nutrients present in the microenvironment…it is more likely that BmpA and B have a role in spirochete survival in the joints”
So the little buggies do manage to survive within joints, and some of the experts know this; including co-authors or supporters of the IDSA guidelines for Lyme disease!
Let’s look at Patent #6,689,364; filed in 2001 and assigned to Tufts University (Boston, MA). Here we see recombinant OspA polypeptides for vaccines. OspA is the outer surface protein A of the Bb spirochete. I speculate about what I believe the Osp proteins to represent — as in which microbial genes comprise this part of the Bb spirochetes. This patent refers to “Bb” spirochetal persistence despite antibiotic therapy:
“Lyme disease generally occurs in three stages…stage three, or late infection, is defined as persistent infection, and can be severely disabling. Chronic arthritis, and syndromes of the central and peripheral nervous system appear during this stage, as a result of the ongoing infection and perhaps a resulting auto-immune disease…Treatment of early disease is usually effective, however the cardiac, arthritis, and nervous system disorders associated with the later stages often do not respond to therapy.”
The key words are “persistent”, “severely disabling”, “chronic”, “ongoing infection”, “often do not respond to therapy”, and “perhaps“. Dr. Baker, your pie is burning, kindly remove it from the oven.
The kind of pseudo-science that we see today, at least in the scope of how conjecture manages to become scientific fact, is patently dangerous to the patients whom suffer miserably with chronic Lyme disease, including those who are unlucky enough never to have been diagnosed at all.
Never mind those whose diagnoses arrive years later when antibiotics and other therapies must work much harder to be effective. Indeed the trends promoted by the spew crew in treating Lyme disease are curiously not unlike a 30-and-out retirement plan, except that these guys are advocating for days of medicine to treat the complex and debilitating persistent Lyme disease, instead of months or even years as is used in other complex illnesses which thrive in immune suppressed bodies, such as cancers or AIDS.
Instead, the same small, tired group of individuals continue to perpetrate the nonsensical and imaginative “diagnosis” of PTLDS despite there being no scientific evidence whatsoever that the syndrome actually exists. Never mind that most of them have never examined any Lyme patients. They remind me of a group of unruly students who must repeat a cooking exam because they keep burning the soufflé, and they have no idea that they must turn the oven temperature down.
If necessary, I would be the first to stand before Dr. Baker and friends to offer my own blood for study and to help them find their missing “evidence-based” medicine. Wait, I have already done this on multiple occasions for another Dr. B.; and the result of those donations? One new, far more sensitive and accurate blood culture test that is able to locate Bb spirochetes in mine and other CDC-seronegative Lyme patients’ blood in less than a week.
But this test would be considered by the Dearborn crew to be “unvalidated” because it is not part of the CDC-recommended diagnostic tests. Yeah, “unvalidated” like the purported post-treatment Lyme disease syndrome. The same kind of evidence-based medicine that can rule in an unsubstantiated syndrome, can rule out a substantiated laboratory test. Did I mention that a certain ELISA test has a patent held by a CDC employee — someone whom may have planned the Dearborn conference? I discuss this and other patents in my books on Lyme.
And by the way, I am entirely RELIEVED to discover that Lyme disease rates have stayed the “same” and that it is a limited infection that is easy to treat with antibiotics. Now I hate to be unappreciative of your baking skills, but excuse me, that pie tastes like (rhymes with my [Lyme-aching] hip).
OK what part of the research do you need to see to convince you that PTLDS is a non-existent entity that should be chucked into the kitchen garbage like the crust of moldy week-old bakery? Check this out:
“The infection, if untreated, commonly persists for months to years despite the occurrence of host antibody and cellular responses; this observation indicates effective evasion of the immune response. Lyme disease may be disabling (particularly in its chronic form), and thus there is a need for effective therapeutic and prophylactic treatment…animal studies indicate that OspA vaccination may not be effective against all strains of Lyme disease Borreliae.”
The inventors listed on this patent included our culture-altering, well-patented Dr. Alan Barbour, and who, along with Dr. Steere, was present at, if not an influential party at the Dearborn conference. He also modified the culture medium that was used in the National Institutes of Health (NIH) laboratory in Montana to identify the Lyme disease spirochete in 1981. From the patent text:
“Lyme disease may be missed or misdiagnosed when it does appear…At present, all stages of Lyme disease are treated with antibiotics. Treatment of early disease is usually effective, however the cardiac, arthritic, and nervous system disorders associated with the later stages often do not respond to therapy (A. C. Steere, ‘Lyme Disease’, New Eng. J. Med., 321, pp. 586-96 (1989)).”
“A. C. Steere” is Connecticut Rheumatologist Dr. Allen C. Steere.
Oh grand pooh-bah of the Lyme disease syndrome speculative arts, if that is not enough, Patent #5,558,993 for Cloned Borrelia burgdorferi virulence protein was filed in June, 1994, and was assigned to the Regents of the University of California. It was created under an NIH grant. The patent represents a Bb “sample” that may be selected from humans, cattle, or swine. The patent also discusses virulence determinant studies and a system that was used for Treponema pallidum (Syphilis) and Leptospira alstoni (an animal spirochete) whereby signal peptides that contained proteins from both organisms were exported in E. coli.
Of interest is an apparent acknowledgement of a leptospiral component to a Bb infection. This is a very different sort of spirochete, and one that I argue scientifically in my books, is the main component of a mutated leptospira called a Leptonema, a critter that Dr. Steere and his team found in a cultured EM rash from a patient in 1981, and which probably led to the quest to find more Bb spirochetes. The complete story of this happenstance is told in my books God Science and also in The Fourth Monkey. According to the patent:
“The dosage ranges for the administration of monoclonal antibodies of the invention are those large enough to produce the desired effect in which the onset symptoms of the leptospiral disease are ameliorated. The dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like.”
This patent describes antigens for animal or human Lyme disease vaccines and diagnostic tests. In case you think the above “leptospiral” reference pertains to a Leptospirosis infection, read this from the patent to clarify:
“1. Field of the Invention: This invention relates generally to an antigenic preparation and specifically to a Borrelia burgdorferi protein (EppA) which is used to induce a protective immune response in animals. This protein can be used immunologically as a vaccine for Lyme disease caused by this organism. Alternatively, diagnosis of Lyme disease can be performed by detecting the presence of the protein, antibody to the protein, or polynucleotide which encodes the protein.”
“Description of Related Art: Lyme disease is an infection with world-wide distribution caused by the spirochete Borrelia burgdorferi, and is the most commonly reported arthropod-borne disease in the United States. About 10,000 reported cases of Lyme disease occur every year in the United States, caused by deer-tick bites that transmit the Borrelia burgdorferi organism. If not identified early, by flu-like symptoms and the bull’s-eye rash that usually appears at the site of infection, untreated Lyme disease can cause heart problems, arthritis, and neurological symptoms. A large group of patients suffer from lasting neurological symptoms, including vision loss, that can recur for years as a result of Lyme disease.”
This patent appears to acknowledge that Lyme disease is a (mutant) Leptospiral infection, just as Dr. Allen Steere et al. found in the Lyme patient’s EM rash. At that time they isolated a novel mutant spirochete which they named Leptospira inadai Lyme. For “some” reason however, neither Dr. Steere nor any of his colleagues have ever seemed to “audibly” inform the public about the relationship of this intermediate form spirochete to a human epidemic called Lyme disease. The only clue to this agent is perhaps a quietly published research paper that practically everyone has overlooked. The previous patent was filed June 1994, just four months before the Dearborn conference.
Patent #5,620,862 for a diagnostic test for early Lyme disease was filed November 1993 and assigned to the University of Connecticut. The patent is for recombinant OspC proteins for diagnostic tests and future vaccines. This is an important patent for an outer surface protein of Bb (OspC) that has yet to be developed into a viable Lyme vaccine, but such development appears to be in progress.
Or Perhaps You May Be Steered by Personal Correspondence:
Let’s examine a 1990 letter written four years before the Dearborn conference which Dr. Steere would attend. In the letter which Dr. Steere wrote to a New York physician, the good Dr. Steere referred to an article by Dr. Preac-Mursic, and discussed the topic of the Bb spirochete, exclaiming:
“Because they were able to culture the spirochete, they certainly proved that one may have persistent infection after intensive antibiotic therapy and despite seronegativity.”
Or How About These gems from the US Armed Forces:
The US Army published a report with excerpts titled Arthropods — Vectors of Disease Agents. The report was dated July 1994, three months before Dearborn, and was authored by Chad P. McHugh. It spoke clearly about Lyme disease:
“Arthropod-borne diseases (ABDs) or, more correctly, etiologic agents transmitted by arthropods cause significant sickness and death worldwide.” The report also stated that Lyme disease is a “chronic, multisystem disease.” As of 1994, Lyme disease was referred to in the military report as “the predominant arthropod-borne disease in the United States.”
At least the military understands Lyme disease. How come the CDC does not? This branch of the US government and public health service was established as a collection of military laboratories. In 1992, correspondence from the commander of the US Army environmental hygiene activity-south at Ft. McPherson, Georgia clearly indicated that the military saw Lyme disease as a “serious health threat,” at least for its service personnel…
This my fellow citizens, Lyme-infected or not, is just the tip of the iceberg as far as evidence I have already published regarding the truth about Lyme disease…and a fraction of what was presented to the Connecticut Attorney General’s office during his anti-trust investigation into the IDSA guidelines for Lyme disease.
The Lyme Disease Epidemic is global, it is growing, ticks are proliferating, they are spreading infectious diseases, and at least one baker and his team of apprentices have their heads in the flour bags.
I think the oven timer is sounding and the (oven) mitts are on. Yup this shoo-fly pie is done, and it does not contain any artificial ingredients, like PTLDS.
Now to practice my pitching technique…one pie in the eye coming up…
 US Patent 5,618,533 . Flavell, et al. Flagellin-based polypeptides for the diagnosis of Lyme disease. Filed 12/10/93 published 4/8/97 . Assignee: Yale University (New Haven, CT). Inventors: Richard A. Flavell, Erol Fikrig, Robert Berland.
 Pal Utpal, Wang Penghua, Bao Fukai, Yang Ziuli, Samanta Swapna, Schoen Robert, Wormser Gary P., Schwartz Ira, Fikrig Erol. Borrelia burgdorferi basic membrane proteins A and B participate in genesis of Lyme arthritis. JEM 2007 Dec 31;9 pages.
 US Patent 6,872 ,55 0. Livey, et al. Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens. Filed 8/19/94 , published 3/29 /05.
 Roxburgh AC. Annual Centrifugal Erythema (“Erythème Annulaire Centrifuge,” Darier, 1916. In: Section of Dermatology. 193 1 June 18. Proc R. Soc Med. 193 1 Oct;24 (12):1645 -1646 .
 Stanek Gerold. Behandlung der Lyme-Borreliose. [Treatment of Lyme Borreliosis]. [Article in German]. Antibiotika Monitor. 2009 May 6.
 US Patent 5,558 ,993 . Champion, et al. Cloned Borrelia burgdorferi virulence protein. Filed 6/17/94 published 9/24 /96 . Assignee: The Regents of the University of California (Oakland, CA).
 US Patent 5,62620,862862862. Padula. Methods for diagnosing early Lyme Disease. Filed 11/2424/9393, published 4/15/9797. Assignee: University of Connecticut (Storrs, CT).
 Copy of letter that appears to be from Dr. Allen C. Steere at Tufts University School of Medicine, New England Medical Center as Chief Rheumatology/Immunology to Dr. Kenneth B. Liegner of Armonk, NY. Dated June 14, 1990.
 Military correspondence from Commanding Officer LTC, MS Joseph A. Jakubowski, Department of the Army, US Army Environmental Hygiene Activity-South, Fort McPherson, GA. Dated October 22 , 1992 . Memorandum for Commander, US Army Training and Doctrine Command, ATTN: ATBO-M, Ft. Monroe, VA and Commander, US Army Health Services Command, ATTN: HSCL-P, Ft. Sam Houston TX. Subject: Lyme disease risk assessment No. 16-62 -AL21-92 , Ft. Jackson, South Carolina, 24 -29 August 1992 .